{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid | 210818-46-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: {3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid
• 英文别名: {[3-({(1R,2S,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl}sulfanyl)propyl]sulfanyl}acetic acid；{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid；2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid
• CAS: 210818-46-5
• 化学式: C₁₈H₃₀O₅S₂
• 分子量: 390.565
• InChiKey: IWJGMNXHWPYORN-XPLDUGHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-异丙基-3-对甲苯基三氮烯 、 {3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid 在 盐酸 、 二氯甲烷 、 Sodium sulfate-III 、 silica gel 、 乙酸乙酯 作用下， 以 丙酮 为溶剂， 反应 1.0h， 以gave 4.3 mg (38%) of the above titled compound的产率得到{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid isopropyl ester
  参考文献：
  名称：

  3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure

  摘要：

  本发明提供了一种治疗眼高压或青光眼的方法，其中包括向患有眼高压或青光眼的动物施用一种由通式I所代表的化合物的治疗有效剂量；其中A，B，D，X，Y，Z，R1，R3和R4如规范中所定义。

  公开号：

  US06538018B1
• 作为产物：
  描述：

  (1E,3S)-1-iodo-3-(tert-butyldimethylsiloxy)-1-octene 在 porcine liver esterase 、 (HF)n*pyridine 、 叔丁基锂 作用下， 以 吡啶 、 phosphate buffer 、 乙醚 、 乙醇 、 乙腈 、 正戊烷 为溶剂， 反应 3.5h， 生成 {3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid
  参考文献：
  名称：

  Design and synthesis of a selective EP4-Receptor agonist. Part 1: discovery of 3,7-DithiaPGE1 derivatives and identification of Their ω chains

  摘要：

  Improvement of EP4-receptor selectivity and the agonist activity by introduction of heteroatoms into the a chain of PGE(1) was investigated. Among the compounds tested, 3,7-dithiaPGE(1) 4a exhibited good EP4-receptor selectivity and agonist activity. Further modification of the omega chain of 3,7-dithiaPGE(1) was performed to improve EP4-receptor selectivity and agonist activity. Of the compounds produced, 16-phenyl-omega-tetranor-3.7-dithiaPGE(1) 4p possessing moderate EP4-receptor selectivity and agonist activity. was identified as a new chemical lead for further optimization by modification of the aromatic moiety. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00351-0

文献信息

• 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
  申请人：Allergan, Inc.

  公开号：US06538018B1

  公开（公告）日：2003-03-25

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; where in A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一定治疗剂量的一种化合物，该化合物由一般式I表示；其中A、B、D、X、Y、Z、R1、R3和R4如规范中定义。
• 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
  申请人：Allergan Sales, Inc.

  公开号：US20030027853A1

  公开（公告）日：2003-02-06

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration, a wavy line represents the &agr; configuration or the &bgr; configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH 2 ; provided that at least one of A or B is S; D represents a covalent bond or CH 2 , O, S or NH; X is CO 2 R, CONR 2 , CH 2 OR, P(O)(OR) 2 , CONRSO 2 R SONR 2 or 2 Y is O, OH, OCOR 2 , halogen or cyano; Z is CH 2 or a covalent bond; R is H, or R 2 ; R 1 is H, R 2 , phenyl, or COR 2 ; R 2 is C 1 -C 5 lower alkyl or alkenyl and R 3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C 1 -C 5 alkyl, halogen, CF 3 , CN, NO 2 , NR 2 , CO 2 R and OR.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一定疗效量的一种化合物，其表示为通用公式I；其中，斜线代表α构型，三角形代表β构型，波浪线代表α构型或β构型，虚线代表双键的存在或不存在；A和B分别选择自O、S和CH2的组合；至少A或B中的一个是S；D代表共价键或CH2、O、S或NH；X为CO2R、CONR2、CH2OR、P(O)(OR)2、CONRSO2R、SONR2或2；Y为O、OH、OCOR2、卤素或氰基；Z为CH2或共价键；R为H或R2；R1为H、R2、苯基或COR2；R2为C1-C5低碳烷基或烯烃基，R3为苯并噻吩基、苯并呋喃基、萘基或其取代衍生物，其中取代基可选择自C1-C5烷基、卤素、CF3、CN、NO2、NR2、CO2R和OR的组合。
• 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
  申请人：Allergan Sales, Inc.

  公开号：US06410591B1

  公开（公告）日：2002-06-25

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective amount of a 3, 7 or 3 and 7 thia or oxa prostanoic acid derivative.

  本发明提供了一种治疗眼压升高或青光眼的方法，包括向患有眼压升高或青光眼的动物施用治疗有效量的3、7或3和7硫或氧代前列腺酸衍生物。
• Treatment of inflammatory bowel disease
  申请人：Burk M. Robert

  公开号：US20050222094A1

  公开（公告）日：2005-10-06

  A method is disclosed herein comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound represented by the general formula I; wherein A, B, D, X, Y, Z, R 1 , R 3 and R 4 are as defined in the specification.

  本文公开了一种方法，包括向患有炎症性肠病的哺乳动物施用一种化合物以治疗该疾病，所述化合物由一般式I表示；其中A、B、D、X、Y、Z、R1、R3和R4如规范中定义。
• Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
  申请人：Allergan Sales, Inc.

  公开号：US20030027846A1

  公开（公告）日：2003-02-06

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein a hatched line represents the &agr; configuration, a triangle represents the &bgr; configuration, a straight line, e.g. at the 9, 11 or 15 position represents either the &agr; or &bgr; configuration, a dotted line represents the presence or absence of a double bond; a wavy line represents a cis or trans bond; X is 0, S, NH or (CH 2 ) n ; n is 0 or an integer of from 1 to 4; Y is C 1 -C 5 n-alkyl, C 3 -C 7 cycloalkyl, phenyl, furanyl, thienyl, pyridinyl, thiazolyl, benzothienyl, benzofuranyl, naphthyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C 1 -C 5 alkyl, halogen, CF 3 , CN, NO 2 , N(R 2 ) 2 , CO 2 R 2 and OR 2 ; Z is (CH 2 ) n or a covalent bond; R is C 1 -C 6 lower alkyl or Z-CF 3 or mesylate or triflate; R 1 is H, R 2 or COR 2 ;and R 2 is H or C 1 -C 5 lower alkyl or 9, 11 or 15 esters thereof.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一种由通式I表示的化合物的治疗有效量；其中，虚线表示α构型，三角形表示β构型，直线，例如在9、11或15位置表示α或β构型，点线表示双键的存在或缺失；波浪线表示顺式或反式键；X为0、S、NH或（CH2）n；n为0或1至4的整数；Y为C1-C5烷基、C3-C7环烷基、苯基、呋喃基、噻吩基、吡啶基、噻唑基、苯并噻吩基、苯并呋喃基、萘基或其取代衍生物，其中取代基可以选择自C1-C5烷基、卤素、CF3、CN、NO2、N（R2）2、CO2R2和OR2的群；Z为（CH2）n或共价键；R为C1-C6低烷基或Z-CF3或甲烷磺酸盐或三氟甲磺酸盐；R1为H、R2或COR2；R2为H或C1-C5低烷基或其9、11或15酯。